Clinical Trials Logo

Byler Disease clinical trials

View clinical trials related to Byler Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT02094222 No longer available - Byler Disease Clinical Trials

Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease

Start date: n/a
Phase:
Study type: Expanded Access

Byler Disease is the result of a homozygous missense (G308V) mutation in the ATP8B1 gene. The disease is typically manifest in the first year of life on the basis of complications of cholestasis; common presentations include jaundice, poor growth, bleeding related to vitamin K deficiency, and/or weak bones related to vitamin D deficiency. Early management of Byler Disease is directed at nutritional issues which tend to be responsive to medical intervention, unlike the pruritus/scratching which remains a devastating problem. Progressive liver disease develops in Byler Disease and can lead to cirrhosis and end-stage liver disease. This is an open label expanded access protocol of RAVICTI in children with Byler Disease. The primary hypothesis is that the administration of RAVICTI in these children is feasible, well tolerated and safe. It is also hypothesized that RAVICTI treatment leads to an improvement in biochemical markers of liver disease and it may ameliorates or prevents the development of scratching behavior as a manifestation of pruritus attributed to the liver disease.

NCT ID: NCT01949766 No longer available - Byler Disease Clinical Trials

Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease

Start date: n/a
Phase: N/A
Study type: Expanded Access

This is a single patient compassionate use protocol to determine whether RAVICTI will improve bile flow in a subject who previously tolerated therapy with Buphenyl.

NCT ID: NCT01784718 No longer available - Byler Disease Clinical Trials

Buphenyl Therapy for Byler's Disease

Start date: n/a
Phase: N/A
Study type: Expanded Access

This is a single patient compassionate use protocol to determine whether Buphenyl (4-phenylbutyrate) will improve the poor bile flow associated with Byler Disease.